Development of Phenothiazine-Based Theranostic Compounds That Act Both as Inhibitors of β-Amyloid Aggregation and as Imaging Probes for Amyloid Plaques in Alzheimer’s Disease
- 18 January 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 8 (4) , 798-806
Abstract
Early detection of Alzheimer’s disease (AD) is imperative in enabling the understanding and clinical treatment of this disorder, as well as in preventing its progression. Imaging agents specifically targeting Aβ plaques in the brain and the retina may lead to the early diagnosis of AD. Among them, near-infrared fluorescent (NIRF) imaging has emerged as an attractive tool to noninvasively identify and monitor diseases during the preclinical and early stages. In the present study, we report the design, synthesis, and evaluation of a series of new near-infrared fluorescent probes. Most of these probes displayed maximum emission in PBS (>650 nm), which falls in the good range for NIRF probes. Among them, 4a1 showed the highest affinity toward Aβ aggregates (Kd = 7.5 nM) and an excellent targeting ability for Aβ plaques in slices of brain and retina tissue from double transgenic mice. These compounds are also found to effectively prevent Aβ fibril formation and disaggregate preformed Aβ fibrils, showing a promising potential as theranostic agents for the diagnosis and therapy of AD.Keywords
Funding Information
- China Postdoctoral Science Foundation (2015M572280)
- China Science Foundation (21672043)
This publication has 25 references indexed in Scilit:
- 2016 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2016
- Prevention of Age-Related Cognitive Decline: Which Strategies, When, and forWhom?Journal of Alzheimer’s Disease, 2015
- Imaging of β-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscienceChemical Society Reviews, 2015
- Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's DiseaseNew England Journal of Medicine, 2014
- Amyloid Chemical Probes and Theranostics: Steps Toward Personalized Medicine in Neurodegenerative Diseases2013
- Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the futureNature Medicine, 2010
- Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s diseaseNature, 2008
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Translating cell biology into therapeutic advances in Alzheimer's diseaseNature, 1999